



ORAL MUCOSITIS INCIDENCE AND SEVERITY AFTER METHOTREXATE-
AND NON-METHOTREXATE-CONTAINING GVHD PROPHYLAXIS REGI-
MENS
Cutler, C.; Li, S.; Kim, H.T.; Laglenne, P.; Ford, C.; Ho, V.; Lee, S.;
Alyea, E.; Soiffer, R.; Sonis, S.; Antin, J. Dana Farber Cancer Institute
and Brigham and Women’s Hospital, Harvard Medical School, Boston,
MA.
Oral mucositis (OM) occurs in up to 75% of recipients of high-
dose chemoradiotherapy conditioning regimens prior to allogeneic
HSCT. As a result of OM, narcotic analgesia and total parenteral
nutrition (TPN) are commonly required after HSCT. Methotrex-
ate (MTX), an antiproliferative GVHD prophylaxis agent, impairs
mucosal regeneration and worsens and prolongs OM. We assessed
the impact of the substitution of sirolimus for MTX as GVHD
prophylaxis on outcomes associated with OM. Methods: 2 patient
cohorts were prospectively analyzed for OM severity and retro-
spectively reviewed for correlative outcomes. All patients under-
went Cy-TBI conditioning and HLA-matched sibling PBSC trans-
plantation. GVHD prophylaxis consisted of sirolimus/tacrolimus
(ST) in the study group and tacrolimus/methotrexate (TM) in the
control group. OM was assessed 3 times per week by members of
the Oral Medicine Service, using a prospectively validated 6-point
assessment tool. Narcotic and TPN use was recorded from the
time of transplantation to hospital discharge. Results: 30 patients
received ST and 24 patients received TM as GVHD prophylaxis
between October 2000 and May 2003. The 2 groups were balanced
for demographic variables, including age, sex, and disease status at
transplant. OM severity was reduced in the ST group. Mild, mod-
erate, and severe OM was noted in 37%, 57%, and 7% of the ST
group and in 8%, 42%, and 50% of the TM group, respectively
(P  .0002). TPN use was reduced in the ST group (17% vs 43%
of hospital days; P  .02), and a higher proportion of subjects
required no TPN in the ST group (47% vs 21%; P  .075). The
total number of narcotic days was lower in the ST group in
comparison with the TM group (median, 13.5 vs. 17 days; P .08),
as was the total mg of morphine-equivalents (MME) administered
per patient (median, 880 vs 1225 mg, P not signiﬁcant [NS]), the
median number of MME per hospital day (41.2 vs 61.7 mg; P 
NS) and the median MME per narcotic day (61.9 vs 95.2 mg; P 
NS). The time to ﬁrst hospital discharge was shorter in the ST
group compared with the TM group (median, 18 vs 22 days; P 
.07). Conclusions: The substitution of sirolimus for methotrexate
as GVHD prophylaxis is associated with a reduction in OM sever-
ity. As a result, TPN and narcotic use are reduced, and hospital-
ization duration is shortened. The use of less toxic GVHD regi-
mens without MTX may have signiﬁcant impact on patient quality
of life, patient outcomes,and economic outcomes associated with
allogeneic stem cell transplantation.
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THE ROLE OF REDUCED-INTENSITY CONDITIONING (RIC) ALLOGENEIC
STEM CELL TRANSPLANTATION (ALLO-SCT) IN PATIENTS WITH ACUTE
MYELOID LEUKEMIA (AML): A DONOR VERSUS NO DONOR COMPAR-
ISON
De Lavallade, H.; Mohty, M.; Faucher, C.; Vey, N.; Coso, D.; Stoppa,
A.M.; Gastaut, J.A.; Ladaique, P.; Chabannon, C.; Blaise, D. Institut
Paoli-Calmettes, Marseille, France.
The role and exact beneﬁt of RIC allo-SCT for AML patients is
still under considerable investigation. Our current policy is to
propose an HLA-identical RIC allo-SCT to AML patients with
high risk leukemic features and with age ( 50 years) and/or
comorbidities precluding the use of standard myeloablative allo-
SCT. We report here a single-center retrospective study that
aimed to evaluate this treatment strategy, and to determine
whether or not all AML patients with high-risk leukemic features
and high-risk clinical features with a suitable HLA-identical sibling
should receive RIC allo-SCT. Between 1999 and 2003, 95 AML
(77% de novo and 23% secondary) patients in complete remission
(93 in ﬁrst CR, 2 in second or third CR) and alive 40 days after
diagnosis were considered as potential candidates for RIC allo-
SCT. Median age was 52 years (range, 26–65). Of the 95 patients,
35 (37%, “donor” group) had an HLA-identical related donor, and
allo-SCT was carried out in 25 (71%) after a RIC based on
ﬂudarabine (150 mg/kg), ATG (2.5 mg/kg), and Bus (8mg/kg). A
total of 60 patients had no donor (63%, “no donor” group). There
were no signiﬁcant differences between the 2 groups with respect
to age, gender, FAB subtype, disease origin (secondary vs de novo)
cytogenetic risk group, history of prior high-dose cytarabine or
autologous transplantation and number of chemotherapy induction
courses. With a median follow-up of 432 days (range, 27–1651), in
an intend-to-treat analysis, LFS was signiﬁcantly higher in the
“donor” group than in the “no donor” group (P  .0096; 54% vs
30.4%, respectively). A total of 32 patients (53%) relapsed in the
no donor group during the follow-up period, as compared to 9
(26%) in the donor group (P .0087). Among the 35 patients with
an HLA-identical related donor, 10 did not receive allo-SCT for
the following reasons: early relapse (2 patients), refusal (4), toxicity
of previous chemotherapy (2), and psychiatric disorder appeared on
therapy (2). For the transplanted patients, little procedure-related
toxicities were observed, and the cumulative incidence of trans-
plant-related mortality was low (12%; 95%CI, 3%-32%) for this
group of elderly high-risk AML patients. We conclude that a
potent graft-versus-leukemia effect can be induced in AML pa-
tients after RIC allo-SCT, with a signiﬁcant beneﬁt in term of
leukemia-free survival.
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SIROLIMUS AND TACROLIMUS AS GRAFT-VERSUS-HOST DISEASE PRO-
PHYLAXIS IN ALLOGENEIC STEM CELL TRANSPLANTATION: THE DANA
FARBER CANCER INSTITUTE EXPERIENCE
Cutler, C.; Li, S.; Kim, H.T.; Alyea, E.; Ho, V.; Lee, S.J.; Soiffer, R.;
Antin, J. Dana-Farber Cancer Institute and Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA.
Sirolimus is a novel immunosuppressant that inhibits T-cell
function through FKBP12/mTOR and can impair dendritic cell
function. Sirolimus acts synergistically with tacrolimus and has a
nonoverlapping toxicity proﬁle, making their use in combination
attractive. We began using sirolimus as GVHD prophylaxis in
2000, and herein describe our experience in the myeloablative
setting. Methods: Two clinical trials were performed using Cy/
TBI conditioning with sirolimus (3–12 ng/ml) and tacrolimus
(5–10 ng/ml) as GVHD prophylaxis. Trial 1 enrolled 76 subjects
who received HLA-matched unrelated or 1-Ag mismatched related
or unrelated bone marrow or peripheral blood stem cells. Abbre-
viated methotrexate (20 mg/m2 total) was given posttransplant.
Trial 2 enrolled 53 subjects who received HLA-matched related
peripheral blood stem cells. No methotrexate was given posttrans-
plant. Results: The median times to neutrophil engraftment (
500/l) were 17 days (range, 11–32) for trial 1 and 14 days (range,
9–17) for trial 2. The median times to platelet engraftment (
20,000/l) were 29 days (range, 11–98) for trial 1 and 12 days
(range, 10–47) for trial 2. Grade II-IV acute GVHD occurred in
35% of the patients in trial 1 and in 19% of the patients in trial 2.
Grade III-IV acute GVHD occurred in 21% of patients in trial 1
and in 4% of patients in trial 2. Toxicity related to the addition of
sirolimus was modest. Among all patients (n  129), VOD oc-
curred in 12%, idiopathic pneumonia syndrome occurred in 7%,
and thrombotic microangiopathy occurred in 10%. The median
time to ﬁrst hospital discharge was 33 days from transplantation for
trial 1 and 19 days from transplantation for trial 2. The percentage
of patients who did not survive to ﬁrst hospital discharge was 9%
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in trial 1 and 6% in trial 2, and total 100-day treatment-related
mortality was 13% in trial 1 and 6% in trial 2. The incidence of
chronic GVHD in the 2 trials was 49% and 44%, respectively. At
2 years, the relapse-free and overall survival estimates for trial 1 are
46% and 48%, respectively (median follow-up, 27 months). One
year relapse-free and overall survival estimates for trial 2 are 71%
and 75%, respectively (median follow-up, 11 months). Overall
survival at 2 years is 72%. Conclusions: Sirolimus, when added to
tacrolimus after allogeneic stem cell transplantation, is effective as
GVHD prophylaxis. Engraftment is prompt, and transplant-re-
lated morbidity and mortality is reduced. Survival estimates are
excellent due to reduced GVHD and transplant-related toxicity.
Sirolimus is worthy of broader study in allogeneic transplantation.
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SIROLIMUS AND THROMBOTIC MICROANGIOPATHY AFTER ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Cutler, C.; Henry, N.L.; Li, S.; Kim, H.T.; Magee, C.; Alyea, E.; Ho,
V.; Soiffer, R.; Antin, J. Dana Farber Cancer Institute and Brigham
and Women’s Hospital, Harvard Medical School, Boston, MA.
Sirolimus (SRL) is a novel immunosuppressive agent that can
reduce GVHD and minimize morbidity after allogeneic stem cell
transplantation (SCT). Thrombotic microangiopathy (TMA) is
characterized by microangiopathic hemolysis, thrombocytopenia,
and renal dysfunction and is associated with calcineurin inhibitors
(CIs). To determine whether SRL use potentiates the effects of CIs
on TMA incidence and risk factors, we performed a retrospective
cohort analysis of subjects who underwent SCT between 1997 and
2003. Methods: Subjects who received a SRL-containing GVHD
prophylaxis regimen were compared with a cohort who received a
non-SRL regimen. All subjects received CIs. Diagnosis of TMA
required the simultaneous occurrence of (1) creatinine elevation 
2 mg/dl or  50% above baseline, (2) schistocytosis, (3) elevated
LDH, and (4) no evidence of DIC. Results: The 111 patients who
received SRL were compared with 216 patients who received no
SRL. The 2 groups of patients were balanced for demographic
parameters; however, more patients in the SRL group received
PBSC transplants (50.5 vs 18.1%; P  .01) and had unrelated
donors (58.6 vs 42.6%, P  .01). The incidence of TMA was
higher in the SRL group than in the non-SRL group (10.8% vs
4.2%; OR  2.57, P  .03). SRL patients developed TMA earlier
than did non-SRL patients (median, 25 days vs 58 days; P  .04).
At TMA diagnosis, median blood levels of immunosuppressive
medications were all within their respective therapeutic ranges. In
a multivariable logistic regression model, only the use of SRL
(adjusted exact OR  3.49, P  .02) and grade II-IV acute GVHD
(adjusted exact OR  6.60, P  .0002) predicted the occurrence of
TMA. Treatment of TMA consisted of discontinuation or dose
adjustment of CIs and SRL. Two subjects in each group required
temporary hemodialysis, and 3 subjects (1 SRL, 2 non-SRL) un-
derwent plasmapheresis. A total of 78% of surviving SRL-treated
subjects regained normal renal function. No subject had a TMA
recurrence if SRL was reintroduced. CIs were never reintroduced.
Overall survival after TMA diagnosis was better for SRL patients
than for non-SRL patients (58.3% vs 11.1%; log rank P  .02).
Conclusion: SRL is associated with an increased risk of TMA after
SCT and may act by potentiating the effects of CIs. TMA associ-
ated with SRL appears to be reversible and does not affect overall
survival after SCT. A careful monitoring strategy for TMA should
be used as part of a SRL-containing GVHD prophylaxis regimen.
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PALIFERMIN (A RHUKGF MOLECULE) IS SAFE AND WELL TOLERATED
IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES (HM) UNDERGO-
ING HIGH-DOSE CHEMORADIOTHERAPY (HD-CRT) FOLLOWED BY AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Blazar, B.R.1; Weisdorf, D.J.1; DeFor, T.E.1; Goldman, A.I.1; Silver,
S.2; Ferrara, J.L.M.2 1. University of Minnesota, Minneapolis, MN; 2.
University of Michigan, Ann Arbor, MI.
The major limitation of allogeneic HSCT is graft-versus-host-
disease (GVHD), a complication where the skin, gastrointestinal
(GI) tract, and liver are damaged by cytokine effectors. Palifermin
has a growth-enhancing differentiation and cytoprotective effect in
the oral and GI mucosa and may be useful as a GVHD prophylaxis.
Previously, we demonstrated that palifermin signiﬁcantly reduced
the incidence, duration, and severity of oral mucositis (OM) in the
autologous HSCT setting. Two animal studies demonstrated pali-
fermin could prevent mucositis and GVHD after CRT. In this
investigator-initiated, randomized, double-blind, placebo-con-
trolled, dose-escalation trial, the safety of palifermin administra-
tion to HM patients undergoing HD-CRT following by allogeneic
HSCT was evaluated. Methods: Patients were entered into 1 of 3
sequentially-enrolled dose/schedule cohorts involving administra-
tion of study drug (placebo or palifermin) on days 11, 10, 9,
0, 1, and 2 relative to HSCT (day 0). Three additional doses were
given to each sequential cohort: stage 1 (3 pretreatment/3 post-
treatment), stage 2 (3 pretreatment/6 posttreatment), or stage 3 (3
pretreatment/9 posttreatment). Adverse events (AEs) were col-
lected continuously. Patients were followed for safety for 100 days
and for survival/relapse for 1 year. Results: A total of 100 patients
(31 placebo, 69 palifermin [8 receiving 40 g/kg/day and 61 re-
ceiving 60 g/kg/day]) were randomized to stage 1, 2, or 3. Time
to engraftment for ANC and platelets was similar between treat-
ment groups. No signiﬁcant differences in the incidence or severity
of GVHD, survival, or relapse rates were observed between treat-
ment groups. Overall, 20 patients (2 placebo, 18 palifermin) dis-
continued the study. Of these, 6 patients (2 placebo, 4 palifermin)
experienced a total of 11 dose-limiting toxicities (DLTs). Discon-
tinuations and DLTs were most common in patients who received
at least 6 doses of study drug after engraftment (day 0). Eighteen
patients (5 placebo, 13 palifermin) died before day 100, due pri-
marily to treatment complications. Palifermin appeared to have a
beneﬁcial effect on OM, but no effect was observed on diarrhea.
Conclusion: Palifermin administration in the allogeneic treatment
setting was safe and well tolerated and did not have any negative
effects on engraftment, GVHD, or survival rates.
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ADOPTIVE TRANSFER OF IN VITRO-GENERATED T CELL PRECURSORS
ENHANCES POSTTRANSPLANT DONOR T CELL RECONSTITUTION IN
RECIPIENTS OF AN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Zakrzewski, J.L.1; Kochman, A.1; Muriglan, S.J.1; Lu, S.1; Kim,
T.D.1; Zuniga-Pﬂucker, J.C.2; Alpdogan, O.1; van den Brink, M.R.M.1
1. Memorial Sloan Kettering Cancer Center, New York, NY; 2. Sun-
nybrook and Women’s College Health Sciences Centre, University of
Toronto, Toronto, ON, Canada.
Recent studies have shown that murine T cells and their precur-
sors can be generated from hematopoietic stem cells (HSC) in vitro
using a novel OP9-DL1 co-culture system consisting of OP9 bone
marrow stromal cells expressing Delta-like 1 Notch ligand (which
binds to the Notch 1 receptor) and growth factors (interleukin 7
and fms-like tyrosine kinase-3 ligand). In this study we determined
the effects of ex vivo-generated T cell precursors on T cell recon-
stitution after allo HSCT. We selected Lin-, Sca-1hi, and c-kithi
HSC from donor bone marrow and cultured these on a monolayer
of OP9-DL1 cells in the presence of growth factors. These
HSC expanded 850-5000-fold and consisted of 95% CD4-CD8
double-negative (DN) T cell precursors after 16–28 days of
culture. We infused these cells (8  106) with T-cell- depleted
(TCD) BM (5  106) into allogeneic recipients. Control mice
received TCD BM only. To determine the effects on T cell
reconstitution after allo HSCT we analyzed thymi and spleens
at days 14 and 29 after transplant by ﬂow cytometry. Progeny
of OP9-DL1 T cell precursors was found on days 14 and 29 in
both thymus and spleen, including 40% (	 20%) of thymo-
cytes and 25% (	 9%) of splenic T cells on day 14 posttrans-
plant and 3.6% (	 2.4%) of thymocytes and 33% (	 7%) of
splenic T cells on day 29 posttransplant. The thymic cellularity was
increased up to 50% on day 14 posttransplant in the OP9-DL1
HSCT group compared to the control group. Splenic T cell
numbers were not increased in OP9-DL1 recipients; however,
donor T cell chimerism was enhanced signiﬁcantly 88.5% vs 65%).
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